Effects of intravenous and inhaled levosimendan in severe rodent sepsis

Intensive Care Medicine

Volumn 35, Issue 8, 2009, Pages 1412-1419

  Scheiermann, Patrick ^a   Ahluwalia, Devan ^b   Hoegl, Sandra ^a   Dolfen, Andrea ^b   Revermann, Marc ^b   Zwissler, Bernhard ^a   Muhl, Heiko ^b   Boost, Kim A ^a   Hofstetter, Christian ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apoptosis; Cecal ligation and incision; Cytokines; Levosimendan; Rat; Severe sepsis

Indexed keywords

CASPASE 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOSIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HYPOTENSION; LAPAROTOMY; MALE; METABOLIC ACIDOSIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SEPSIS;

ADMINISTRATION, INHALATION; ANIMALS; HUMANS; HYDRAZONES; INJECTIONS, INTRAVENTRICULAR; MODELS, ANIMAL; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RODENTIA; SEPSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67650815896     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-009-1481-9     Document Type: Article

References (35)

1. A Padkin C Goldfrad AR Brady D Young N Black K Rowan 2003 Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales, and Northern Ireland Crit Care Med 31 2332 2338
2. MM Levy MP Fink JC Marshall E Abraham D Angus D Cook J Cohen SM Opal JL Vincent G Ramsay 2003 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference Intensive Care Med 29 530 538
3. RP Dellinger MM Levy JM Carlet J Bion MM Parker R Jaeschke K Reinhart DC Angus C Brun-Buisson R Beale T Calandra JF Dhainaut H Gerlach M Harvey JJ Marini J Marshall M Ranieri G Ramsay J Sevransky BT Thompson S Townsend JS Vender JL Zimmerman JL Vincent 2008 Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008 Intensive Care Med 34 17 60
4. M Kivikko L Lehtonen 2005 Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure Curr Pharm Des 11 435 455
5. S Archan W Toller 2008 Levosimendan: current status and future prospects Curr Opin Anaesthesiol 21 78 84
6. A Mebazaa MS Nieminen M Packer A Cohen-Solal FX Kleber SJ Pocock R Thakkar RJ Padley P Poder M Kivikko 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 1883 1891
7. M Fries C Ince R Rossaint C Bleilevens J Bickenbach S Rex EG Mik 2008 Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock Crit Care Med 36 1886 1891
8. M Behrends J Peters 2003 The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts Intensive Care Med 29 1802 1807
9. A Dubin G Murias JP Sottile MO Pozo M Baran VS Edul HS Canales G Etcheverry B Maskin E Estenssoro 2007 Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study Intensive Care Med 33 485 494
10. A Morelli S De Castro JL Teboul M Singer M Rocco G Conti L De Luca E Di Angelantonio A Orecchioni NG Pandian P Pietropaoli 2005 Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression Intensive Care Med 31 638 644
11. A Strasser L O'Connor VM Dixit 2000 Apoptosis signaling Annu Rev Biochem 69 217 245
12. DE Wesche JL Lomas-Neira M Perl CS Chung A Ayala 2005 Leukocyte apoptosis and its significance in sepsis and shock J Leukoc Biol 78 325 337
13. M Louhelainen E Vahtola P Kaheinen H Leskinen S Merasto V Kyto P Finckenberg WS Colucci J Levijoki P Pollesello H Haikala EM Mervaala 2007 Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats Br J Pharmacol 150 851 861
14. KA Boost S Hoegl A Dolfen H Czerwonka P Scheiermann B Zwissler C Hofstetter 2008 Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury Crit Care Med 36 1873 1879
15. D Cunha-Goncalves V Perez-de-Sa P Dahm E Grins J Thorne S Blomquist 2007 Cardiovascular effects of levosimendan in the early stages of endotoxemia Shock 28 71 77
16. P Scheiermann S Hoegl M Revermann D Ahluwalia J Zander KA Boost T Nguyen B Zwissler H Muhl C Hofstetter 2009 Cecal ligation and incision: an acute onset model of severe sepsis in rats J Surg Res 151 132 137
17. KA Boost M Flondor C Hofstetter I Platacis K Stegewerth S Hoegl T Nguyen H Muhl B Zwissler 2007 The beta-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia Acta Anaesthesiol Scand 51 900 908
18. C Hofstetter KA Boost M Flondor E Basagan-Mogol C Betz M Homann H Muhl J Pfeilschifter B Zwissler 2007 Anti-inflammatory effects of sevoflurane and mild hypothermia in endotoxemic rats Acta Anaesthesiol Scand 51 893 899
19. C Hofstetter M Flondor S Hoegl E Thein G Kemming H Kisch-Wedel W Kreyling B Zwissler 2004 Aerosol delivery during mechanical ventilation to the rat Exp Lung Res 30 635 651
20. S Hoegl KA Boost M Flondor P Scheiermann H Muhl J Pfeilschifter B Zwissler C Hofstetter 2008 Short-term exposure to high-pressure ventilation leads to pulmonary biotrauma and systemic inflammation in the rat Int J Mol Med 21 513 519
21. PR Rosevear N Finley 2003 Molecular mechanism of levosimendan action: an update J Mol Cell Cardiol 35 1011 1015
22. H Yokoshiki Y Katsube M Sunagawa N Sperelakis 1997 Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes Eur J Pharmacol 333 249 259
23. S Szilagyi P Pollesello J Levijoki H Haikala I Bak A Tosaki A Borbely I Edes Z Papp 2005 Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone J Cardiovasc Pharmacol 46 369 376
24. MS Nieminen J Akkila G Hasenfuss FX Kleber LA Lehtonen V Mitrovic O Nyquist WJ Remme 2000 Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 1903 1912
25. S Antila M Kivikko L Lehtonen J Eha A Heikkila P Pohjanjousi PJ Pentikainen 2004 Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan Br J Clin Pharmacol 57 412 415
26. S Singh TW Evans 2006 Organ dysfunction during sepsis Intensive Care Med 32 349 360
27. E Rivers B Nguyen S Havstad J Ressler A Muzzin B Knoblich E Peterson M Tomlanovich 2001 Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 345 1368 1377
28. M Varpula M Tallgren K Saukkonen LM Voipio-Pulkki V Pettila 2005 Hemodynamic variables related to outcome in septic shock Intensive Care Med 31 1066 1071
29. RA Zager AC Johnson S Lund SY Hanson CK Abrass 2006 Levosimendan protects against experimental endotoxemic acute renal failure Am J Physiol Renal Physiol 290 F1453 F1462
30. RS Hotchkiss PE Swanson JP Cobb A Jacobson TG Buchman IE Karl 1997 Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice Crit Care Med 25 1298 1307
31. RS Hotchkiss CM Coopersmith IE Karl 2005 Prevention of lymphocyte apoptosis - a potential treatment of sepsis? Clin Infect Dis 41 Suppl 7 S465 S469
32. RS Hotchkiss KC Chang PE Swanson KW Tinsley JJ Hui P Klender S Xanthoudakis S Roy C Black E Grimm R Aspiotis Y Han DW Nicholson IE Karl 2000 Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte Nat Immunol 1 496 501
33. R Oberbeck D Schmitz K Wilsenack M Schuler B Pehle M Schedlowski MS Exton 2004 Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis Neuroimmunomodulation 11 214 223
34. R Oberbeck D Schmitz K Wilsenack M Schuler B Husain M Schedlowski MS Exton 2006 Dopamine affects cellular immune functions during polymicrobial sepsis Intensive Care Med 32 731 739
35. R Oberbeck D Schmitz M Schuler K Wilsenack M Schedlowski M Exton 2004 Dopexamine and cellular immune functions during systemic inflammation Immunobiology 208 429 438